Optieum Biotechnologies develops antibody-based therapies utilizing the Eumbody System to create optimized single-chain variable fragments (scFvs) for generating CAR-T cells with enhanced anti-tumor efficacy. Their technology addresses the challenge of treating refractory cancers by improving the proliferation and longevity of CAR-T cells, leading to better patient outcomes and reduced side effects.
Funding
$11.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CAR-T cell therapies face challenges in effectively treating solid tumors and hematological malignancies due to limitations in CAR design, which can affect T-cell proliferation, longevity, and anti-tumor efficacy. Traditional methods of CAR design may not achieve the optimal activation threshold for T-cells, leading to suboptimal immune responses and potential antigen escape.
Solution
Optieum Biotechnologies is developing next-generation CAR-T cell therapies using its Eumbody System, a proprietary CAR discovery engine that optimizes the binding domain of CAR constructs to enhance immune cell function. The Eumbody System employs empirical methodologies to identify optimized single-chain variable fragments (scFvs), which are then used to create CAR-T cells with improved proliferative capacity and reactivity against advanced tumor profiles. By dynamically harmonizing scFv sequences, Optieum aims to achieve the precise level of stimulation that triggers T-cells to become fully and appropriately active, resulting in more effective and durable anti-tumor responses. The company's pipeline includes programs targeting solid tumors (FAPa) and hematological malignancies/autoimmune disorders (CD19).
Target Audience
The primary target audience includes patients with refractory cancers, particularly solid tumors and hematological malignancies, as well as those with autoimmune disorders who may benefit from CAR-T cell therapies.
Features
- Eumbody System: A CAR discovery engine that optimizes scFv sequences for enhanced T-cell function.
- Empirical methodologies to identify optimized CAR constructs.
- Next-generation CAR constructs engineered to achieve the optimal activation threshold for T-cells.
- Improved proliferative capacity and reactivity against advanced tumor profiles.
- Pipeline programs targeting FAPa for solid tumors and CD19 for hematological malignancies/autoimmune disorders.